Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell ...
Ibrutinib is indicated for the treatment of the following conditions.
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Waldenström's macroglobulinemia
Chronic graft-versus-host disease (cGVHD)
Mantle cell lymphoma (MCL)
Marginal zone lymphoma (MZL)
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Washington University, School of Medicine, Saint Louis, Missouri, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Mass General Hospital Cancer Center, Boston, Massachusetts, United States
University of Athens, Athens, Greece
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Alexandra Hospital, Athens, Greece
Praxis Dr. Vehling-Kaiser, Landshut, Germany
Kliniken Ostalb, Staufenklinikum Schw. Gmuend, Mutlangen, Germany
Northside Hospital, Atlanta, Georgia, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
George Washington Cancer Center, Washington, District of Columbia, United States
Moffitt Cancer Center, Tampa, Florida, United States
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China/Zhejiang Province, China
the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.